Anticholinergic use is linked with cognitive impairment, falls and mortality in human observational studies, with independent labs reporting these associations again. Dementia links vary, and a study links use with lower mortality in people with dementia receiving antidepressants. Some papers declare company ties.
85 findings in 58 papers from 2016 to 2026, 8 of them since April 2026
Independent labs found the same change in people. 47 independent labs in 20 countries; 2 trials, none about aging.
“individuals with anticholinergic drugs prescribed had significantly higher odds of being diagnosed with dementia (adjusted odds ratio, 1.50 [95% confidence interval, 1.47-1.54]).”
Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
47 independent labs in 20 countries
5 findings against
2 trials, none about aging
Funders: National Institute on Aging and others
10 of 73 findings with company ties
Humans62
In silico1
What did studies of anticholinergics find?
18
Studies of anticholinergics measured 18 outcomes; the most studied is cognitive function (7 studies).
Cognitive function
↓downin humans7
7 studies
Anticholinergics are linked with worse cognitive function in neuropsychiatric unit patients (r = -0.178, p = 0.039).
“The correlation between ACB burden and MMSE was negative and significant (r = -0.178; p = 0.039)”
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·
Anticholinergics are linked with worse cognitive function in humans (Alzheimer's disease spectrum) (CV-BF = 9.0).
“moderate evidence for an association of anticholinergic burden with baseline levels of cognitive impairment for the PACC5 as a global cognitive function score (CV-BF = 9.0)”
Anticholinergics are linked with worse cognitive function in humans (-1.74 and -1.70/year vs -1.26/year, p < 0.01).
“MMSE decrease was steeper in patients with moderate and high Drug Burden Index ( -1.74 and -1.70/year, respectively) than in patients with no exposure (-1.26/year)”
Humansafter adjusting for age, education, anxiety and depressive disorders, functional autonomy, and behavioural disorders
Anticholinergics were not clearly linked with mortality in humans (emergency laparotomy).
“There was no significant difference in mortality up to 1 year following surgery between those with or without polypharmacy, nor those with or without significant ACB.”
Anticholinergics were not clearly linked with brain atrophy in humans (Alzheimer's disease spectrum).
“anticholinergic burden had only a modest effect on cognitive decline and no effect on atrophy in brain regions that are related to the cholinergic system.”
Anticholinergics are linked with worse executive function in humans (Alzheimer's disease spectrum) (CV-BF = 2.5).
“weak evidence for an association of anticholinergic burden with longitudinal rates of change in the trail-making test B as an executive function score (CV-BF = 2.5)”
Anticholinergics are linked with worse grip strength in humans (6-year WCE model, per 1-unit increase in weighted mSDD) (MD per year, -0.0329 [95% CI -0.0612 to -0.0046] kg).
“the 6-year WCE model had the lowest QIC (MD per year, -0.0329 [95% CI -0.0612 to -0.0046] kg).”
Humans6-year WCE model, per 1-unit increase in weighted mSDDn = 4,200
Anticholinergics are linked with worse gait speed in humans (10-year TSDD 1096 or greater vs nonusers) (MD per year, -0.0132 [95% CI, -0.0193 to -0.0070] m/s).
“Compared with nonusers, a greater decline rate in gait speed was found for those with 10-year TSDD 1096 or greater (MD per year, -0.0132 [95% CI, -0.0193 to -0.0070] m/s)”
Humans10-year TSDD 1096 or greater vs nonusers8.2 years of follow-upn = 4,210
Anticholinergics were not clearly linked with Alzheimer's disease or related dementias onset in humans (Prostate cancer; regardless of primary treatment modality) (P = .06).
“PDE5i (P = .07) and AC (P = .06) were not associated with dementia regardless of primary treatment modality.”
HumansProstate cancer; regardless of primary treatment modalityMedian use 12.2 monthsmalesn = 5,937
Studies link anticholinergics with 24 measures, most often dementia (14 studies), mortality (10) and falls (6).
Dementia
↑upin humans14HR 1.006–1.52
14 studies
Anticholinergics are linked with a higher risk of dementia in humans (vs. beta-3 agonists only, adjusted for age, sex, comorbidities, and psychotropic drug use) (OR 1.53, 95% CI 1.10-2.14).
“The adjusted odds ratio (OR) and 95% confidence interval (CI) for OAB anticholinergics were 1.53 (95% CI: 1.10-2.14, p = 0.0110)”
Humansvs. beta-3 agonists only, adjusted for age, sex, comorbidities, and psychotropic drug use
Anticholinergics are linked with a higher risk of dementia in humans (adjusted models) (median OR 1.09-1.10 vs 1.05-1.06).
“Odds ratios for death, dementia, and delirium using anticholinergic-polypharmacy pseudoscales (median = 1.09-1.10) were greater than those of general-polypharmacy pseudoscales (1.05-1.06).”
The journals of gerontology. Series A, Biological sciences and medical sciences·
Anticholinergics are linked with a higher risk of dementia in humans (older surgical patients after major surgery) (HR 1.006; 95% CI 1.003-1.008).
“Each one-order increase in inpatient anticholinergic medications was associated with a 0.60% increase in dementia risk (HR 1.006; 95% CI 1.003-1.008).”
Anticholinergics are linked with a higher risk of dementia in humans (overactive bladder) (aHR 1.22, 95% CI 1.15-1.30).
“there was an increased risk of dementia in the anticholinergic drug group compared to the beta-3 agonist group (adjusted hazard ratio [aHR] = 1.22; 95% confidence interval [CI], 1.15-1.30).”
Anticholinergics are linked with a higher risk of dementia in humans (adjusted odds ratio 1.18 (95% CI 1.16 to 1.20)).
“The adjusted odds ratio for dementia associated with the use of any anticholinergic drug used to treat an overactive bladder was 1.18 (95% confidence interval (CI) 1.16 to 1.20)”
Anticholinergics are linked with a higher risk of dementia in humans (relative to those with no exposure) (OR 2.7, 95% CI 2.2-3.3).
“high doses of anticholinergic medications were associated with increased odds of dementia at 1 y relative to those with no exposure (odds ratio 2.7; 95% confidence interval 2.2-3.3)”
Humansrelative to those with no exposuresix or more dosesduring hospital stayn = 39,665
Anticholinergics are linked with a higher risk of dementia in humans (aOR 1.50 (95% CI 1.47-1.54)).
“individuals with anticholinergic drugs prescribed had significantly higher odds of being diagnosed with dementia (adjusted odds ratio, 1.50 [95% confidence interval, 1.47-1.54]).”
Anticholinergics are linked with a higher risk of dementia in humans (1.6 to 2.6 times increased risk (95% CI 1.4-1.9 to 1.1-6.3)).
“ACH exposure to one, two, three and four or more ACH medications was associated with a 1.6 (95% CI 1.4-1.9), 2.1 (95% CI 1.7-2.8), 2.6 (95% CI 1.5-4.4), and 2.6 (95% CI 1.1-6.3) times, respectively, increased risk of a dementia/Alzheimer's disease diagnosis”
Anticholinergics are associated with dementia in humans (Patients with overactive bladder without baseline cognitive impairment) (HR 1.52 (95% CI 1.29–1.80); nonlinear inverted U-shaped relationship, peaking at approximately 874 cumulative defined daily dose (HR 1.63, 95% CI 1.32–2.00)).
“ACH use was associated with significantly increased dementia risk (HR: 1.52; 95% CI: 1.29-1.80).”
ReviewPatients with overactive bladder without baseline cognitive impairmentn = 7,891,574
Anticholinergics are linked with a higher risk of mortality in humans (adjusted models) (median OR 1.09-1.10 vs 1.05-1.06).
“Odds ratios for death, dementia, and delirium using anticholinergic-polypharmacy pseudoscales (median = 1.09-1.10) were greater than those of general-polypharmacy pseudoscales (1.05-1.06).”
The journals of gerontology. Series A, Biological sciences and medical sciences·
Anticholinergics are linked with a higher risk of mortality in humans (post discharge) (hazard ratio: 2.98, 95% confidence interval (0.96-9.28)).
“an ACB score of ≥ 3 at discharge was marginally associated with one-year mortality post discharge [hazard ratio: 2.98, 95% confidence interval (0.96-9.28)].”
Anticholinergics are linked with a higher risk of mortality in humans (1.4 to 3.8 times increased risk (95% CI 1.2-1.6 to 2.6-5.4)).
“ACH exposure to one, two, three and four or more medications was associated with a 1.4 (95% CI 1.2-1.6), 2.6 (95% CI 2.1-3.3), 3.8 (95% CI 2.6-5.4), and 3.4 (95% CI 1.8-6.4) times, respectively, increased risk of mortality”
Anticholinergics are linked with a higher risk of mortality in humans (hip fracture surgery) (OR 2.5 (CI: 2.0-3.1)).
“The 30-day mortality increased from 7% for patients with ACB score of 0 to 16% for patients with ACB score of ≥5, corresponding to an adjusted OR 2.5 (CI: 2.0-3.1).”
Humanship fracture surgery90 days before surgeryn = 31,443
Anticholinergics are linked with a lower risk of mortality in patients with dementia receiving antidepressants (HR 0.88; 95% CI 0.79-0.98; p = 0.023).
“There was a reduced mortality risk in people receiving agents with high central anticholinergic burden compared to those with no or low burden which was statistically significant in the antidepressant cohort”
Humansin patients with dementia receiving antidepressants
Anticholinergics are associated with mortality in humans.
“long-term use of medicines with anticholinergic activity is associated with worsening of cognitive function, increased incidence of dementia and increased mortality”
Anticholinergics raise the risk of mortality in humans (frailty).
“Observed associations included reduced ability for chair standing, slower gait speeds, poorer physical performance, increased risk of falls and mortality.”
Journal of intellectual disability research : JIDR·
Anticholinergics are associated with falls in humans (baseline) (OR 1.412, 95% CI 1.035-1.926).
“Logistic regression revealed an independent association between ACB 1-2 and falls at baseline (odds ratio, OR (95% confidence interval, CI) =1.412(1.035-1.926))”
Anticholinergics raise the risk of falls in humans.
“higher cumulative anticholinergic burden is associated with increased risks of cognitive impairment, delirium, falls, functional decline, and possibly dementia.”
Anticholinergics raise the risk of cognitive impairment in humans.
“higher cumulative anticholinergic burden is associated with increased risks of cognitive impairment, delirium, falls, functional decline, and possibly dementia.”
Anticholinergics raise the risk of bone fracture in humans (regardless of the anticholinergic burden scale used) (pooled RR 1.28, 95% CI 1.18-1.39).
“Meta-analysis indicated a positive relationship between use of anticholinergic drugs and fracture risk, regardless of the anticholinergic burden scale used.”
Reviewregardless of the anticholinergic burden scale usedn = 487,247
Anticholinergics are linked with a higher risk of delirium in humans (adjusted models) (median OR 1.09-1.10 vs 1.05-1.06).
“Odds ratios for death, dementia, and delirium using anticholinergic-polypharmacy pseudoscales (median = 1.09-1.10) were greater than those of general-polypharmacy pseudoscales (1.05-1.06).”
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·
Anticholinergics are linked with a higher risk of mild behavioral impairment in humans (adjusted for 10-year mortality risk, age, sex, education, and race) (HR 1.07, 95% CI 1.02-1.14).
“When assessed as a time varying covariate, ACB score was associated with incident MBI (HR 1.07, 95% CI 1.02-1.14, p = 0.010).”
Humansadjusted for 10-year mortality risk, age, sex, education, and race5.64 yearsn = 4,865
Anticholinergic use was associated with higher incident dementia risk compared with β3-agonist use (hazard ratio, 1.49; 95% CI, 1.04–2.13).Anticholinergic use was associated with higher incident dementia risk compared with β3-agonist use (hazard ratio, 1.49; 95% CI, 1.04–2.13).
Caregiver surveys of 512 autistic adults with higher support needs linked higher anticholinergic medication scores to memory problems and changes associated with…Caregiver surveys of 512 autistic adults with higher support needs linked higher anticholinergic medication scores to memory problems and changes associated with cognitive decline.